Screening for early cognitive impairment: “rapid changes ahead”

Recent advances in identifying markers of cognitive change are set to change the way that we think about detecting and treating the earliest signs of cognitive impairment and Alzheimer’s disease (AD).

We are identifying changes earlier, and developing accurate tools for predicting risk of progression. Now that disease-modifying therapies are starting to become available, population screening for early-stage AD could soon move rapidly from concept to reality.